The Sci-tech Innovation Board has been open for more than a month. As the only two medical stocks listed in the first batch of Sci-tech Innovation Board, Endovastec and Nanjing Micro-Tech have developed into “CNY-One-Hundred-Priced Stocks” on the day of listing. As of September 11, the closing price of Endovastec was CNY149.84/share, with a market value of CNY 10.556 billion; while the closing price of Nanjing Micro-tech was CNY138.09/share, with a market value of CNY 18.22 billion.
Both of the above-mentioned enterprises belong to the medical device field, and the first set of listing standards is adopted: the market value is not less than CNY 1 billion, the net profit in the last two years is lucrative and the accumulated net profit is not less than CNY 50 million, or the estimated market value is not less than CNY 1 billion, the net profit in the most recent year is lucrative and the operating income is not less than CNY 100 million.
In the past year, there have been two new liquidity opportunities in biomedical field in China. (1) HKEX opened the door for unprofitable biopharmaceutical enterprises, which spawned a series of “biotech stocks” that invigorated liquidity of biological medicine in China in the early stage; (2) the Sci-tech Innovation Board provided new financing channels for hard technology companies with high R&D investment and vulnerable short-term profits, and took the lead in stimulating the liquidity of the medical device industry.
Both of the above-mentioned enterprises belong to the medical device field, and the first set of listing standards is adopted: the market value is not less than CNY 1 billion, the net profit in the last two years is lucrative and the accumulated net profit is not less than CNY 50 million, or the estimated market value is not less than CNY 1 billion, the net profit in the most recent year is lucrative and the operating income is not less than CNY 100 million.
In the past year, there have been two new liquidity opportunities in biomedical field in China. (1) HKEX opened the door for unprofitable biopharmaceutical enterprises, which spawned a series of “biotech stocks” that invigorated liquidity of biological medicine in China in the early stage; (2) the Sci-tech Innovation Board provided new financing channels for hard technology companies with high R&D investment and vulnerable short-term profits, and took the lead in stimulating the liquidity of the medical device industry.